FibroBiologics (FBLG) CEO receives 92,410 options vesting over 4 years

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

FibroBiologics, Inc. reported that its Chief Executive Officer, O'HEERON PETE, received a grant of stock options. The award covers 92,410 options to buy common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.

According to the vesting schedule, one quarter of the option shares will vest on the one-year anniversary of the May 4, 2026 grant date. The remaining shares will vest in 36 equal monthly installments, provided the CEO remains in continuous service. Following this grant, the filing shows 92,410 derivative securities held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider O'HEERON PETE

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	92,410	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 92,410 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options Granted: 92,410 options Exercise Price: $1.38 per share Expiration Date: May 4, 2036 +2 more

5 metrics

Options Granted 92,410 options Stock option grant to CEO on May 4, 2026

Exercise Price $1.38 per share Stock option exercise price for CEO grant

Expiration Date May 4, 2036 Option term for CEO stock option grant

Post‑grant derivative holdings 92,410 options Total derivative securities following transaction

Initial vesting 1/4 after one year Portion vesting on first anniversary of grant date

Key Terms

Stock Option (Right to Buy), exercise price, vest, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.3800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"option shares shall vest on the one-year anniversary of the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continuous service financial

"until fully vested so long as the reporting person remains in continuous service"

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 07:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'HEERON PETE

(Last)

(First)

(Middle)

C/O FIBROBIOLOGICS, INC.

9350 KIRBY DRIVE, SUITE 300

(Street)

HOUSTON

TEXAS

77054

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.38	05/04/2026		A		92,410		⁽¹⁾	05/04/2036	Common Stock	92,410	$0	92,410	D

Explanation of Responses:

1. On May 4, 2026, the reporting person was granted an option to purchase 92,410 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.

	/s/ Ruben A. Garcia, by Power of Attorney	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did FibroBiologics (FBLG) disclose for its CEO?

FibroBiologics disclosed that its CEO received a grant of stock options covering 92,410 shares. These options are a compensation-related award, not an open‑market stock purchase, and give the right to buy common shares at a fixed $1.38 exercise price.

How many FibroBiologics stock options were granted to the CEO in this Form 4?

The Form 4 reports a grant of 92,410 stock options to the CEO. Each option represents the right to purchase one share of common stock, creating a direct derivative holding of 92,410 options immediately following the reported transaction.

What is the exercise price and expiration date of the FibroBiologics CEO options?

The CEO’s stock options have an exercise price of $1.38 per share and expire on May 4, 2036. This means the CEO can choose to buy common shares at $1.38 any time before that expiration, once the relevant tranches have vested.

How do the FibroBiologics CEO stock options vest over time?

The options vest over roughly four years. One quarter of the 92,410 options vests on the one‑year anniversary of the May 4, 2026 grant, while the remaining three quarters vest in 36 equal monthly installments, contingent on continuous service.

Is the FibroBiologics CEO’s Form 4 transaction a market purchase or a compensation grant?

The transaction is a compensation grant, not a market purchase. It is coded as a grant or award acquisition of derivative securities, providing stock options at a $1.38 exercise price rather than reporting any open‑market buying or selling of existing common shares.